Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine
Chantal G. Lemay(University of Ottawa), Rebecca C. Auer(Ottawa Hospital), Jean‐Simon Diallo(University of Ottawa), Harold Atkins(University of Ottawa), Jennifer M Paterson(University of Ottawa), Agnieszka Kuś(University of Ottawa), Vera A. Tang(University of Ottawa), Barbara C. Vanderhyden(University of Ottawa), John C. Bell(Ottawa Hospital), Vanessa da Silva Garcia(University of Ottawa), Byram W. Bridle(PhytoCeutica (United States)), Kenneth Garson(Ottawa Hospital), David F. Stojdl(Ottawa Regional Cancer Foundation), Fabrice Le Bœuf(Ottawa Hospital), Lisa Ferreira(Discovery Centre), Julia L. Rintoul(University of Ottawa), Brian D. Lichty(McMaster University Medical Centre), Rozanne Arulanandam(Ottawa Hospital), Theresa Falls(Ottawa Hospital), Kelley A. Parato, David P. Conrad(Ottawa Hospital)
Cited by 93
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary
|New England Journal of Medicine|2009|775
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503